Biotech's Next Big Thing: Earnings
It's time to review the mid-cap biotech stocks reporting second quarter results next week, says Adam Feuerstein, Sr. Columnist at TheStreet.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.
